NCT04305613Active, not recruiting
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy: A Prospective Longitudinal Cohort
Source: ClinicalTrials.gov · Last updated 5 Oct 2026
Brief summary (registry, in English)
This observational cohort will evaluate the cardiovascular effects of chemoradiation used to treat locally advanced, non-small cell lung cancer. Patients will be enrolled prior to the start of therapy and followed during and for at least 2 years after therapy with echocardiograms, nuclear stress tests, blood sampling, and quality of life surveys.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 221 (estimated)
- First submitted
- 10 Mar 2020
- Start date
- 14 Sept 2020
- Primary completion date
- Dec 2026
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Diseases
- Lung cancer
- NCT number
- NCT04305613
What you commit to
- Study type: Observational
- Planned participants: 221
- From 14 Sept 2020 to the primary completion date, Dec 2026
- 8 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatment with anthracyclines
Other illness
- Radiation treatment not expected to involve any heart exposure as determined by treating provider
- Contraindication to rest/vasodilator stress PET/CT, including: asthma with ongoing wheezing at time of enrollment; known Mobitz Type II AV block, 3rd degree AV block, or sick sinus syndrom, without a pacemaker; systolic blood pressure less than 90mmHg; known hypersensitivity to Regadenoson and adenosine; profound sinus bradycardia (heart rate less than 40bpm).
Other
- Pregnant or breast-feeding
- ECOG performance status greater than 2
- Vulnerable patients, including pregnant women and prisoners
Who the study is looking for
- At least 18 years of age
- Histologically confirmed or clinically diagnosed non-small cell lung cancer where the plan is for definitive treatment that includes radiation
- Able to give written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Alabama Coordinator of this site? Confirm its status | Birmingham | United States | Unknown status |
| The Brigham and Women's Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| Lancaster General Hospital Coordinator of this site? Confirm its status | Lancaster | United States | Unknown status |
| Rutger's University / Cancer Institute of New Jersey Coordinator of this site? Confirm its status | New Brunswick | United States | Unknown status |
| Abramson Cancer Center of the University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
| Washington University School of Medicine Coordinator of this site? Confirm its status | St Louis | United States | Unknown status |
| Montefiore Medical Center Coordinator of this site? Confirm its status | The Bronx | United States | Unknown status |
| Chester County Hospital Coordinator of this site? Confirm its status | West Chester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.